A 43-year-old woman with a history of depression, which was being treated with oxcarbazepine twice a day (300 mg/morning and 450 mg/evening), was started on lamotrigine 2 weeks prior to her presentation, with the dose increased to 50 mg/day just prior to admission.
INTRODUCTION
Anticonvulsant hypersensitivity syndrome (AHS) is a severe idiosyncratic reaction to antiepileptic drugs [1] . Anticonvulsant hypersensitivity syndromes are typically associated with antiepileptic drugs containing a benzene ring, such as phenytoin, phenobarbital, carbamazepine and lamotrigine. Mucosal and skin involvement feature prominently with lamotrigine use [2] . There are very few reports associating lamotrigine with severe hepatotoxicity [3] [4] [5] [6] [7] [8] . We believe this to be the first case reported of a patient with extremely high liver enzymes (AST/ALT Ͼ1000 IU/L) when lamotrigine was added to oxcarbazepine treatment, with eventual complete resolution of symptoms and enzyme levels after termination of the medication and supportive management.
an emergency department (ED), where she was found to have elevated liver enzymes. The aspartate aminotransferase (AST) was 2764 IU/L, alanine aminotransferase (ALT) was 2490 IU/L, total bilirubin was 0.4 mg/dL (6.8 mol/L), and alkaline phosphatase was 93 IU/L. She was instructed to stop all her medications and was discharged with oral antihistamines, and a follow-up appointment was arranged with a primary care physician. Two days later, the patient developed chills, fatigue, and persistent nausea. She sought treatment in an urgent care facility, where the liver enzymes were repeated and showed an alarming elevation: AST, 6079 IU/L; ALT, 6900 IU/L; total bilirubin, 3.9 mg/dL (66.7umol/L); alkaline phosphatase, 149 IU/L; international normalized ration (INR), 1.9; prothrombin time, 21.5 seconds; creatinine, 0.7 mg/dL (61.9 mol/L); white cells 5.3 x 103/L (7% eosinophils); platelets 219 x 103/L; hemoglobin, 14.0 g/dL; hematocrit, 41%; albumin, 3.8 g/dL; blood urea nitrogen, 8 mg/dL (2.9 mmol/L). Serology tests for hepatitis A, B, and C were negative. Cardiac enzymes were normal. Abdominal ultrasound was obtained, which was normal. The patient denied taking any mushrooms, herbs, or any other medications other than lamotrigine and oxcarbazepine in the prescribed manner. She did not have any recent travel and she had no history of alcohol or recreational drug abuse. She was not known to have any allergic tendencies or previous drug allergies.
The patient showed no signs of encephalopathy. Her vital signs were normal and there was no fever. Clinical examination was essentially normal except for very mild jaundice and a diffuse erythematous pruritic macular rash. There were no intraoral lesions, lymphadenopathy, or hepatosplenomegaly. Although the patient did not feel ill, she was admitted for observation and investigation.
Management included intravenous hydration and supportive care. She did not have any clinical signs or symptoms of bleeding but was started prophylactically on oral vitamin K and a proton pump inhibitor (Protonix). An antihistamine (diphenhydramine) was prescribed for symptomatic relief of her itching. No systemic steroids were prescribed.
On the third day of hospitalization, her liver enzymes had improved substantially and she was discharged: AST, 1676 IU/L; ALT, 3907 IU/L; INR, 1.2; prothrombin time, 15.3 seconds. The patient discontinued all her medications after discharge.
At follow-up 1 month later, the patient's liver enzymes were within the normal range: AST, 27 IU/L; ALT, 69 IU/L; INR, 1.1; prothrombin time, 14.0 seconds.
DISCUSSION
AHS is a type of drug hypersensitivity syndrome involving anticonvulsants [1] . While it occurs in only a small proportion of patients, it is associated with considerable morbidity and even mortality [2] .
Lamotrigine is an anticonvulsant that inhibits voltagedependent sodium channels, thereby stabilizing neuronal membranes and reducing the release of excitatory neurotransmitters, particularly glutamate and aspartate [9] . It has antidepressant efficacy [10] and has been used for managing bipolar depression [11] .
We report a woman with lamotrigine-associated hepatitis who recovered spontaneously with supportive treatment. We believe that this is the first reported case of severe acute hepatitis when lamotrigine was added to oxcarbazepine in the treatment of a depressed patient.
We hypothesize that lamotrigine was directly responsible for the patient's rash and liver impairment given the time sequence of drug introduction and resolution of symptoms and liver enzyme abnormality once the drug was withdrawn.
The patient had been taking oxcarbazepine without any complications for the past year. She developed symptoms 2 weeks into her therapy with lamotrigine, which is the classic indication of AHS [1, 2] . There was a documented significant rise in liver enzymes within 2 days and recovery of liver function when the anticonvulsants were stopped. Her only symptoms were nausea and a diffuse erythematous macular rash. Previous case reports [3] [4] [5] [6] [7] [8] of lamotrigine-induced AHS with severe hepatotoxicity have described fever and some signs of encephalopathy or hepatic decompensation. Our patient did not have any fever and was mentally and neurologically normal, which was unlike most previously reported patients with severe hepatic involvement.
The greatest risk of rash appears to be during the first 8 weeks of treatment [12] . The overall rate of rashes for patients taking lamotrigine is 13% [12] ; any rash in such patients is potentially serious and should be evaluated promptly [13] . Although the patient was sent home after her initial visit to the ED, relying on outpatient treatment with antihistamines or corticosteroids is inadequate and not recommended, as the role of these agents are uncertain [14] .
In a systematic review of 26 patients with lamotrigine-associated AHS [15], lamotrigine was being used concomitantly with other antiepileptic drugs such as carbamazepine or valproate. This patient was taking oxcarbazepine, a structural derivative of carbamazepine [16] . There have not been any previous reports of oxcarbazepine-associated hepatitis or hepatic failure in an adult. There was, however, a case of a child with an acute severe hepatitis associated with oxcarbazepine use [17] . However, the temporal course (onset after addition of lamotrigine) made the association of AHS with oxcarbazepine unlikely, although the concomitant anticonvulsant administration may have interacted with lamotrigine metabolism.
In a retrospective evaluation, the influence of oxcarbazepine on lamotrigine serum concentrations was investigated [18] . Administration of oxcarbazepine decreased lamotrigine serum concentrations by approximately 29% due to the inducing effect of oxcarbazepine on lamotrigine. This could lead to an accumulation of its metabolites, which in turn may precipitate the immune reaction. In another study, lamotrigine increased concentrations of the active 10-mono-hydroxy metabolite of oxcarbazepine [19] . It is unknown if these changes in concentration are clinically important, although it may be necessary to adjust the dose of oxcarbazepine when starting, stopping, or changing the dose of oxcarbazepine. However, the dosage of medication is irrelevant if the hepatitis was due to a hypersensitivity reaction.
There was no serological evidence of viral hepatitis or any history of use of other hepatotoxic drugs, or ingestion of herbal medicine or mushrooms. Hepatotoxicity during lamotrigine therapy was also thought to be related to a specific patient profile such as systemic complications or status epilepticus [5] , but our patient had no prior history of drug or alcohol abuse and no other medical history such as liver impairment. She had no seizures or evidence of rhabdomyolysis. There was no other significant intervention done other than supportive and symptomatic management. Although oral corticosteroids have been used with good outcome in case reports [20, 21] , our patient made an uneventful recovery with supportive care, and systemic steroids were never started.
It may be prudent to monitor the hepatic function in patients who have just been initiated on lamotrigine if they develop jaundice, especially if they are also taking another anticonvulsant. In such an event, the immediate discontinuation of the medication should be accompanied by vigorous resuscitation and supportive care to prevent further morbidity or mortality [6] .
CONCLUSION
We believe this to be the first case reported of a patient with severe transaminitis (AST/ALT Ͼ1000 IU/L) when lamotrigine was added to oxcarbazepine, which resolved after termination of the medication and supportive management.
Concomitant antiepileptic drug with lamotrigine may increase the risk of AHS.
Relying on outpatient treatment with antihistamines or corticosteroids is inadequate; it may be prudent to monitor the hepatic function in patients who have just been initiated on lamotrigine, especially if they develop jaundice.
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